{"id":"low-intensity-warfarin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (minor)"},{"rate":null,"effect":"Bleeding (major)"},{"rate":null,"effect":"Warfarin necrosis"},{"rate":null,"effect":"INR elevation/over-anticoagulation"}]},"_chembl":{"chemblId":"CHEMBL1464","moleculeType":"Small molecule","molecularWeight":"308.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Warfarin is a coumarin anticoagulant that antagonizes vitamin K, reducing the synthesis of vitamin K-dependent coagulation factors. Low-intensity dosing aims to achieve a lower International Normalized Ratio (INR, typically 1.5–2.0) compared to standard warfarin therapy (INR 2.0–3.0), potentially reducing hemorrhagic complications while maintaining thromboprophylactic efficacy in select patient populations.","oneSentence":"Low-intensity warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) at reduced doses to provide anticoagulation with a lower bleeding risk profile.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:26.864Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboprophylaxis in patients at risk for venous thromboembolism"},{"name":"Stroke prevention in atrial fibrillation (at reduced intensity)"}]},"trialDetails":[{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT07081035","phase":"PHASE4","title":"Trial of Low-intensity Anticoagulation to Reduce GI or Other Bleeding Complications With Equivalent Therapeutic Efficacy in HeartMate 3 LVAD Patients","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-10","conditions":"Advanced Heart Failure, Left Ventricular Assist Devices, Anticoagulation Treatment","enrollment":94},{"nctId":"NCT03078374","phase":"NA","title":"MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)","status":"UNKNOWN","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2017-01-11","conditions":"Heart Failure, Cardiovascular Diseases","enrollment":15},{"nctId":"NCT01996657","phase":"","title":"D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement","status":"COMPLETED","sponsor":"Wuhan Asia Heart Hospital","startDate":"2013-01","conditions":"Heart Valve Disease","enrollment":772},{"nctId":"NCT02646267","phase":"PHASE4","title":"The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-03","conditions":"Atrial Fibrillation","enrollment":210},{"nctId":"NCT01438580","phase":"PHASE4","title":"The Effect and Safety of Different Intensity Anticoagulation Therapy in Elderly Patients With Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Nanjing Medical University","startDate":"2010-01","conditions":"Atrial Fibrillation","enrollment":260},{"nctId":"NCT00125671","phase":"PHASE3","title":"Warfarin and Antiplatelet Vascular Evaluation","status":"UNKNOWN","sponsor":"Anand, Sonia, M.D.","startDate":"2000-01","conditions":"Peripheral Vascular Diseases, Cardiovascular Diseases","enrollment":2400},{"nctId":"NCT00157651","phase":"PHASE3","title":"Access II - Trial of Warfarin to Prevent Malfunction of Haemodialysis Catheters","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"1999-02","conditions":"End Stage Renal Disease, Thrombosis, Bleeding","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":80,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"low intensity warfarin","genericName":"low intensity warfarin","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-intensity warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) at reduced doses to provide anticoagulation with a lower bleeding risk profile. Used for Thromboprophylaxis in patients at risk for venous thromboembolism, Stroke prevention in atrial fibrillation (at reduced intensity).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}